We reply within one business dayGet my quote
Thyroid cancer: US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Thyroid cancer: the short answer
The US FDA has approved four medicines on this page for thyroid cancer, each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Lenvima, Cabometyx, Retevmo and Gavreto.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is thyroid cancer?
Thyroid cancer starts in the thyroid, a butterfly-shaped gland in the front of the neck that makes hormones controlling how the body uses energy. The main types are differentiated thyroid cancer (papillary and follicular), medullary thyroid cancer and anaplastic thyroid cancer.[1]
Risk is higher in women, in people aged 25 to 65, in people exposed to head or neck radiation, and in those with a goiter, certain genetic conditions or a family history. It may cause no symptoms at first. Later signs include a lump in the neck, trouble breathing or swallowing, and hoarseness.[1]
Most thyroid cancers are treated with surgery and often radioactive iodine. For advanced cancers that no longer respond to radioactive iodine, or with specific gene changes such as RET, US-approved targeted tablets are used.[2, 3]
Thyroid cancer in the Gulf
A review of thyroid cancer in the GCC states reported that it was the second most common cancer in all GCC states except Bahrain and Kuwait, where it ranked third, and that Qatar had the highest incidence in women (13.5 per 100,000).[4]
US FDA-approved medicines for thyroid cancer
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Lenvima (lenvatinib)
FDA-approved for adults with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. It is a capsule.[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India - Cabometyx (cabozantinib)
FDA-approved for adults and children 12 years and older with locally advanced or metastatic differentiated thyroid cancer that progressed after VEGFR-targeted therapy and is radioactive iodine-refractory or ineligible. It is a tablet.[7]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India - Retevmo (selpercatinib)
FDA-approved for adults and children 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, or advanced thyroid cancer with a RET gene fusion, who need systemic therapy. It is taken by mouth.[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman - Gavreto (pralsetinib)
FDA-approved for adults and children 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who need systemic therapy and are radioactive iodine-refractory where relevant. It is a capsule.[8]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[5, 6]
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[9, 10] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for thyroid cancer
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for thyroid cancer?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Lenvima, Cabometyx, Retevmo and Gavreto. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Lenvima available in Saudi Arabia or the UAE?
Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Lenvima?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
What does radioactive iodine-refractory mean?
It means the cancer no longer responds to radioactive iodine treatment. Several US labels on this page are for this situation.
Is thyroid cancer common in the Gulf?
A GCC review found it was the second most common cancer in most GCC states, with the highest female incidence in Qatar.
Sources for the last two answers: [2, 7] [4]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus (US National Library of Medicine): Thyroid Cancer
- DailyMed (US National Library of Medicine): Lenvima (lenvatinib) US prescribing information, version published 8 October 2026
- DailyMed (US National Library of Medicine): Retevmo (selpercatinib) US prescribing information, version published 14 September 2026
- Al-Zahrani et al. Epidemiology of thyroid cancer: a review with special reference to Gulf Cooperation Council (GCC) states. Gulf J Oncolog 2007 (PubMed 20084720)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- DailyMed (US National Library of Medicine): Cabometyx (cabozantinib) US prescribing information, version published 17 November 2025
- DailyMed (US National Library of Medicine): Gavreto (pralsetinib) US prescribing information, version published 28 January 2026
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Non-small cell lung cancer
- Renal cell carcinoma
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
- यह पृष्ठ हिंदी में पढ़ें
This page is general health information, not medical advice. It does not replace a consultation with your doctor.